For many years, Alzheimer’s disease has been one of the biggest challenges in medicine. It slowly damages memory, thinking, and daily life, affecting millions of older adults around the world.
Scientists have spent decades searching for treatments that can slow or stop the disease, and for a time, a group of drugs targeting a substance called amyloid brought new hope.
Amyloid is a protein that builds up in the brains of people with Alzheimer’s disease. It forms sticky clumps, often called plaques, which were long believed to be a key cause of the illness. Based on this idea, researchers developed drugs designed to remove amyloid from the brain, hoping this would slow down memory loss and other symptoms.
Recently, two drugs called lecanemab and donanemab were approved in the United States and Europe. They were widely described as major breakthroughs because early studies suggested they could slow the disease. Many people hoped these treatments would finally change the course of Alzheimer’s disease.
However, a new large review has raised serious questions about whether these drugs truly help patients. The study was carried out by the Cochrane organization and published in the Cochrane Database of Systematic Reviews. Cochrane is known for carefully reviewing large amounts of medical evidence, making its findings highly influential.
The researchers looked at data from 17 clinical trials involving more than 20,000 people with early-stage Alzheimer’s disease or mild memory problems. These studies tested several drugs that all aim to remove amyloid from the brain.
The results showed that while these drugs do remove amyloid, they do not lead to meaningful improvements in patients’ memory or daily functioning.
Some small changes were seen in tests, but they were too minor to make a real difference in everyday life. This is important because a treatment needs to improve how people feel or function, not just change numbers in a study.
At the same time, the review found risks linked to these drugs. Patients were more likely to develop swelling or bleeding in the brain. These changes were often seen in scans, even if patients did not notice symptoms. The long-term effects of these risks are still not fully understood.
These findings challenge a long-standing belief in Alzheimer’s research. For decades, many scientists thought that removing amyloid would directly help patients. This study suggests that this idea may not be correct, at least for the current generation of drugs.
However, not all experts agree with the conclusions. Some scientists argue that the review grouped together different drugs, including older ones that are known to be less effective. They believe this may have reduced the apparent benefits of newer treatments.
Other researchers point out that even if these drugs are not very effective now, amyloid may still play a role in the disease. Future treatments targeting amyloid in different ways could still prove helpful.
Overall, this review provides a careful and detailed look at existing evidence. It suggests that current anti-amyloid drugs may not deliver the benefits many had hoped for. However, it also highlights the complexity of Alzheimer’s disease and the need for continued research.
In conclusion, while these drugs once raised great hope, their real-world impact appears limited. This does not mean progress has stopped, but it does show that scientists may need to explore new ideas and different targets to find better treatments for Alzheimer’s disease.
If you care about Alzheimer’s, please read studies about the likely cause of Alzheimer’s disease , and new non-drug treatment that could help prevent Alzheimer’s.
For more health information, please see recent studies about diet that may help prevent Alzheimer’s, and results showing some dementia cases could be prevented by changing these 12 things.
